<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526837</url>
  </required_header>
  <id_info>
    <org_study_id>BSSNY-B-001</org_study_id>
    <nct_id>NCT01526837</nct_id>
  </id_info>
  <brief_title>Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence</brief_title>
  <official_title>A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brain &amp; Spine Surgeons of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brain &amp; Spine Surgeons of New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into
      the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first
      recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigators decision
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of bevacizumab (Avastin) following local administration.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>All adverse events will be recorded in the case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be followed for survival as well as disease progression for 12 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>bevacizumab (Avastin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.</description>
    <arm_group_label>bevacizumab (Avastin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recurrent Glioblastoma

          2. At least 12 weeks expected survival (KPS &gt;60)

          3. 18 years of age or older

          4. Able and willing to participate

        Exclusion Criteria:

          1. Any prior diagnosis of any other cancer or other concurrent malignancy.

          2. Planned use or current use of other investigation therapy.

          3. Systemic autoimmune disease

          4. HIV positive

          5. Concurrent life threatening disease

          6. Impaired organ function

          7. Active infection

          8. Inadequately controlled hypertension

          9. Congestive heart failure

         10. Myocardial infection/unstable angina within 6 months

         11. Stroke within 6 months

         12. Pheripheral vascular disease

         13. History of abdominal fistula/gastrointestinal performation

         14. Non-healing wound

         15. Coagulation disease

         16. Known allergy to study treatments

         17. Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Abrahams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain &amp; Spine Surgeons of New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Strack</last_name>
    <role>Study Director</role>
    <affiliation>BSSNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain &amp; Spine Surgeons of New York</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brain &amp; Spine Surgeons of New York</investigator_affiliation>
    <investigator_full_name>John Abrahams, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Brain tumor</keyword>
  <keyword>GBM</keyword>
  <keyword>Brain cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

